June 13, 2026 • 20 mins
A tiny smudge in a century-old medical paper might be one of the most useful clues we have for Alzheimer’s disease prevention today. We trace that smudge back to 1907, when Alois Alzheimer documented not only plaques and tangles, but also lipid accumulation inside glial cells, a finding the field largely shrugged off for decades. Once you add modern genetics, especially ApoE4 and its role in lipid transport, the idea that cholesterol and brain health are deeply linked stops sounding like a stretch and starts sounding like unfinished science.
From there, we dig into Tobias Hartman’s 2026 editorial and the clinical data behind it, including a massive 10-year cohort study of nearly 50,000 people. The numbers are easy to mock at first glance: changes like 0.01 or 0.17 on the Clinical Dementia Rating Sum of Boxes (CDRSB). But we walk through the “time saved” method that converts score differences into something families actually feel: months of cognitive function. It is the difference between a statistic and a calendar, and it reframes why modest effects can still matter in neurodegenerative disease.
Then we wrestle with the catch. Observational data brings confounding. Different statins behave differently. And the most unsettling twist: MRI and cerebrospinal fluid biomarkers like hippocampal atrophy and tau do not significantly improve, even when cognition seems to hold on longer. That tension points toward a bigger possibility: maybe vascular health, endothelial function, and whole-body metabolism help determine how long the brain can cope with underlying pathology. If you want a clear-eyed, nuance-first guide to statins, Alzheimer’s risk, and why combination strategies like the FINGER protocol may be the real future, listen now, subscribe, and share your take with us in a review.
This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice.
Never miss an episode—subscribe on your favorite podcast app!
Listen
Watch
Mark as Played
Transcript
Episode Transcript
Available transcripts are automatically generated. Complete accuracy is not guaranteed.
SPEAKER_00 (00:00):
Imagine looking at uh like a century-old crime
scene photo.
You know, you were staring atthis grainy image trying to
figure out what happened, andyou realize the most important
clue wasn't the smoking gunlying right in the center of the
room.
SPEAKER_01 (00:12):
Aaron Powell Right.
It's usually somethingcompletely unexpected.
SPEAKER_00 (00:16):
Exactly.
It was just the smudge on thewindow that everyone completely
ignored because they were, Imean, they were too distracted
by the obvious evidence.
SPEAKER_01 (00:23):
Aaron Powell Yeah, that happens a lot in science,
actually.
SPEAKER_00 (00:25):
Aaron Powell It really does.
And if you've ever wondered iffixing your whole body could
actually, you know, save yourmind, well, this deep diet is
entirely for you.
Because back in 1907, the doctorwho first discovered Alzheimer's
left us exactly that kind ofoverlooked clue.
SPEAKER_01 (00:43):
Aaron Powell It is just a phenomenal example of how
scientific progress isn't uhit's not always a straight line.
We often have to dig throughthese historical archives to
make sense of the latestclinical data.
Yeah.
Especially when we are dealingwith a disease that has frankly
outsmarted us for this long.
SPEAKER_00 (01:00):
And the source we are analyzing today forces us to
do exactly that.
We are pulling from an editorialpublished in the 2026 Journal of
Prevention of Alzheimer'sDisease.
SPEAKER_01 (01:10):
Written by Tobias Hartman, right?
SPEAKER_00 (01:11):
Yes, Tobias Hartman.
It is titled Lipid LoweringRegimens in Alzheimer's Disease
Dementia, Small Effects withPotential Long-Terfit?
SPEAKER_01 (01:19):
Quite a mouthful.
SPEAKER_00 (01:20):
It is, yeah.
But the mission for this deepdive is to basically synthesize
this dense medical text andanswer a really specific
critical question.
Can common heart medications, uhspecifically drugs that lower
your cholesterol, actually slowdown the cognitive decline of
Alzheimer's?
SPEAKER_01 (01:39):
Which is a huge question.
SPEAKER_00 (01:41):
Huge.
Okay, let's unpack this.
Because to understand why modernneurologists are suddenly so
obsessed with cholesterol drugs,we have to travel back to the
very first time Alzheimer's wasever officially characterized.
SPEAKER_01 (01:51):
Yeah, we have to go all the way back to Alice
Alzheimer's original 1907 paper.
Right.
When he first examined the braintissue of a patient who had died
from this, well, this mysterioussevere dementia, he identified
three distinct molecularhallmarks under his microscope.
SPEAKER_00 (02:05):
Aaron Ross Powell Three of them.
And we usually only hear abouttwo.
SPEAKER_01 (02:08):
Exactly.
The first two hallmarks becamethe cornerstone of a century of
research.
We are talking aboutneurofibrillary tangles and
amyloid plaques.
SPEAKER_00 (02:18):
The famous plaques and tangles.
SPEAKER_01 (02:20):
Right.
Those two structural anomalieshave just dominated billions of
dollars in funding.
But Alzheimer's actuallydocumented a third hallmark in
that very same paper.
He called them uh glial adiposesacches.
SPEAKER_00 (02:34):
Okay, I have read a lot about plaques and tangles
over the years, but glialadipose sacules is definitely a
new one for me.
SPEAKER_01 (02:41):
It sounds very archaic.
SPEAKER_00 (02:42):
It really does.
Break down thatturn-of-the-century terminology
for it.
SPEAKER_01 (02:45):
Sure.
So in modern biological terms,he was describing intracellular
lipid accumulation.
SPEAKER_00 (02:50):
Aaron Ross Powell Meaning fat inside the cells.
SPEAKER_01 (02:52):
Basically, yeah.
He saw these little droplets offat building up inside the
brain's support cells, which arethe glia.
Wow.
But for the better part of acentury, that observation was
totally sidelined.
I mean, the scientific communitylooked at those fat droplets and
assumed they were just abyproduct of dying brain tissue.
Trevor Burrus, Jr.
SPEAKER_00 (03:08):
Like just trash left over from the damage.
SPEAKER_01 (03:10):
Aaron Ross Powell Exactly.
Kind of like debris left overafter a building collapses, you
know.
The tangles and the plaques wereviewed as the main event.
SPEAKER_00 (03:18):
Okay.
SPEAKER_01 (03:19):
And it wasn't until about 30 years ago that the
journal Science published thisreally provocative article
titled Bad for the Heart, Badfor the Mind, which finally
challenged that wholeassumption.
SPEAKER_00 (03:29):
Aaron Powell And that article started connecting
the dots between cardiovascularhealth and brain health, right?
Trevor Burrus, Jr.
SPEAKER_01 (03:35):
It did.
SPEAKER_00 (03:35):
Because they noticed that statins were doing
something unexpected.
SPEAKER_01 (03:38):
Aaron Powell Yeah.
That science article highlightedsome early epidemiological data
suggesting that statins, whichare, you know,
cholesterol-lowering drugs,might actually lower amyloid
beta in the brain.
But more importantly, itcoincided with a growing
understanding of the genetics ofAlzheimer's.
We realized around then that thestrongest genetic risk factor
(04:01):
for late-onset Alzheimer's is agene variant called ApoE4.
SPEAKER_00 (04:05):
Aaron Ross Powell, which is something anyone who
has taken a commercial DNA testfor health risks has probably
heard of.
Like it pops up all the time.
SPEAKER_01 (04:11):
Oh, absolutely.
It's very well known now.
SPEAKER_00 (04:13):
Aaron Ross Powell But how does ApoE4 actually
connect to those little fatdroplets Alzheimer's song?
SPEAKER_01 (04:18):
Aaron Ross Powell Well, what is remarkable is that
ApoE's literal day job in thehuman body is lipid transport.
It is an apolipoprotein.
Okay.
So its primary function is tophysically carry cholesterol and
other fats through thebloodstream and the brain.
SPEAKER_00 (04:33):
Wow.
So if the biggest genetic riskfactor for the disease is
basically a broken cholesteroldelivery truck.
SPEAKER_01 (04:39):
Exactly.
SPEAKER_00 (04:40):
And Alice Alzheimer saw fat accumulating in the
brain cells all the way back in1907, the connection becomes
kind of undeniable.
SPEAKER_01 (04:49):
It does.
It shows the lipid system isfundamentally involved in the
pathology.
SPEAKER_00 (04:53):
So the historical blind spot wasn't just like a
miss detail.
It was a fundamentalmisunderstanding of the brain's
metabolism.
Right.
Spent decades staring at theplaques, completely ignoring the
fact that the brain's fattransport system was breaking
down right in front of us.
SPEAKER_01 (05:06):
What's fascinating here is how this realization
completely shifted the paradigmof modern prevention strategies.
Also.
Well, we finally recognized thatsystemic factors like elevated
midlife cholesterol are majormodifiable risk factors for the
disease.
SPEAKER_00 (05:22):
Aaron Powell Modifiable meaning we can
actually do something aboutthem.
SPEAKER_01 (05:25):
Exactly.
We stopped looking at the brainas this isolated fortress that
just operates independently ofthe rest of the body.
And that brings us to thepresent day, where researchers
are trying to see if we canmanipulate that cholesterol
system to actually change thecourse of the dementia.
SPEAKER_00 (05:40):
Which brings us to the clinical data at the center
of the Hartman editorial.
Because this isn't justtheoretical biology anymore.
SPEAKER_01 (05:46):
No, not at all.
SPEAKER_00 (05:47):
Hartman focuses on a massive perspective study by
Sternberg and colleagues.
And when I say massive, I meanthey followed nearly 50,000
participants for 10 years.
SPEAKER_01 (05:57):
Aaron Powell It is an incredibly robust data set.
Sternberg's team wanted tomeasure the actual impact of
lipid lowering regimens oncognitive decline over time.
So they tracked participantsmoving from normal cognition
into mild cognitive impairmentor MCI, and then subsequently
into full dementia.
SPEAKER_00 (06:15):
Aaron Powell And how do they measure that?
Like what's the ruler they use?
SPEAKER_01 (06:17):
Aaron Powell To quantify that decline, they use
something called the CDRSB,which stands for Clinical
Dementia Rating Sum of Boxes.
SPEAKER_00 (06:25):
Sum of boxes.
SPEAKER_01 (06:26):
Yeah.
It is a standard scaleneurologist use to score a
patient's memory, orientation,judgment, and personal care.
The higher the score, the worsethe impairment.
SPEAKER_00 (06:36):
Aaron Powell Okay, and with 50,000 people over a
full decade, you get the kind ofstatistical power that can
detect even the tiniestfluctuations in human cognition.
SPEAKER_01 (06:46):
Exactly.
You can see the smallestsignals.
SPEAKER_00 (06:48):
Aaron Powell But I have to bring up the actual
numbers they found.
Because I read this, and for thegroup converting from normal
cognition to mild cognitiveimpairment, the researchers
found a difference of elevenhundredth of a CDRSB point per
year compared to non-users.
SPEAKER_01 (07:02):
That is the reported figure, yes.
An annual difference of.01points.
SPEAKER_00 (07:06):
Wait, eleven hundredth of a point?
SPEAKER_01 (07:08):
Yeah.
SPEAKER_00 (07:08):
Is that even worth putting in a medical journal,
let alone discussing here?
I mean, a human being's mood ona random Tuesday could probably
fluctuate their memory test bymore than eleven hundredth of a
point.
That sounds like a statisticalrounding error, not a medical
breakthrough.
SPEAKER_01 (07:23):
Your skepticism is entirely justified, and you
know, the editorial actuallyvalidates that exact pushback.
In a standard clinical setting,eleven hundredth of a point is
entirely negligible.
Right.
A patient and their family wouldabsolutely never notice that
kind of difference day to day.
But the researchers didn't juststop there.
Okay.
When they stratified the dataand looked at a different subset
(07:44):
of patients, the narrativechanged pretty significantly.
They looked at individuals olderthan 50 who already had a higher
degree of baseline cognitiveimpairment.
SPEAKER_00 (07:52):
So people who are already showing real symptoms.
SPEAKER_01 (07:55):
Yeah, specifically people with a CDRSB score
greater than three.
For that group, the benefit ofthe lipid lowering drugs
increased to a reduction of 0.17points annually.
SPEAKER_00 (08:05):
Okay, well, 0.17 is undeniably larger than 0.01.
SPEAKER_01 (08:08):
Definitely.
SPEAKER_00 (08:09):
But let's be honest, to the average listener trying
to figure out how to help, say,a parent with dementia, 0.17
still sounds pretty microscopic.
SPEAKER_01 (08:17):
It does sound small.
SPEAKER_00 (08:18):
We need to bridge the gap between abstract
clinical statistics and humanreality here.
SPEAKER_01 (08:23):
Uh-huh.
SPEAKER_00 (08:24):
Why does the scientific community care so
much about a 0.17 annualreduction?
SPEAKER_01 (08:29):
Because in neurodegenerative diseases, we
have to translate these abstractpoint scores into the one metric
that actually matters topatients, which is time.
SPEAKER_00 (08:39):
Time.
SPEAKER_01 (08:40):
Yes.
The editorial introduces thisreally brilliant analytical
concept called time saved.
It references the recentmethodological work by
researchers Dixon and Hendricks.
SPEAKER_00 (08:50):
Okay, and what did they do?
SPEAKER_01 (08:52):
They developed a mathematical model to convert
these tiny fractionaldifferences on the CDRSB scale
into actual months of lifegained.
SPEAKER_00 (09:00):
How do they actually calculate that though?
Yeah.
Because time saved sounds greatin a brochure, but how does the
math actually work in a clinicaltrial?
SPEAKER_01 (09:08):
It is based on mapping the trajectory of
decline.
SPEAKER_00 (09:11):
Okay.
SPEAKER_01 (09:11):
Imagine drawing a downward sloping line that
represents how fast the placebogroup is losing their cognitive
function over a year.
SPEAKER_00 (09:17):
Aaron Powell Right.
So a steady slope downwards.
SPEAKER_01 (09:19):
Then you plot the treatment group's decline on the
exact same graph.
Because the treatment group isdeclining slightly slower, say
0.17 points slower, their lineis a bit flatter.
SPEAKER_00 (09:29):
Uh-huh.
SPEAKER_01 (09:30):
The time saved is calculated by looking at where
the treatment group ended up atthe end of the trial, and then
tracing horizontally to see howmany months earlier the placebo
group hit that exact same levelof impairment.
SPEAKER_00 (09:41):
Oh wow.
So it is literally measuring thegap in time between when the two
groups crossed the exact samethreshold of memory loss.
SPEAKER_01 (09:48):
Precisely.
To give you some context for howthis looks in practice, Hendrix
evaluated the high-profileAlzheimer's drug Donamab.
SPEAKER_00 (09:55):
Right.
That's been in the news a lot.
SPEAKER_01 (09:57):
It has.
In its clinical trials, Donomabshowed a CDR SB difference of
0.36 points over 76 weeks.
Okay.
When they ran that trajectorymath, that fractional point
difference translated todelaying the disease progression
by about 5.2 months.
SPEAKER_00 (10:14):
That's almost half a year.
SPEAKER_01 (10:15):
Exactly.
Another intervention they lookedat, Fortis and Connect, showed a
0.6 point difference over 24months, which translated to a
delay of 10.5 months.
SPEAKER_00 (10:25):
Here's where it gets really interesting.
If we apply that trajectory mathto these standard cholesterol
drugs, the whole perspectiveshifts, right?
SPEAKER_01 (10:32):
It really does.
If an older patient with mildimpairment is seeing a 0.17
point reduction annually fromtheir lipid lowering regimen,
you are looking at a compoundingeffect over time.
SPEAKER_00 (10:43):
Aaron Powell I like to think of it like putting
loose change in a jar ratherthan trying to, you know, win
the lottery.
SPEAKER_01 (10:49):
That's a great way to look at it.
SPEAKER_00 (10:50):
Taking a statin isn't going to cure the disease
overnight.
But if you are saving a fractionof a point this year and another
fraction next year and the yearafter that, I mean, over a five
or ten year period, thatcompounding interest suddenly
buys you real meaningful time.
SPEAKER_01 (11:06):
Absolutely.
SPEAKER_00 (11:07):
You are talking about potentially extending a
person's ability to recognizetheir grandchildren or manage
their own household by severalmonths.
SPEAKER_01 (11:16):
If we connect this to the bigger picture, this is
exactly why the scientificcommunity is paying so much
attention.
Yeah.
A sustained compoundingreduction of 0.17 points
annually transforms what lookslike a modest statistical blip
into a profoundly meaningfulclinical outcome.
Buying six months of cognitiveindependence is a triumph in
Alzheimer's care.
SPEAKER_00 (11:37):
It is a massive triumph.
But wait, if this compoundingmath is so incredibly promising,
why isn't every neurologist onthe planet just aggressively
prescribing cholesterolmedications specifically for
dementia right now?
SPEAKER_01 (11:50):
Well, that's the catch.
SPEAKER_00 (11:51):
Right.
What is the catch in the data?
Because we cannot give you, thelistener, the impression that
statins are this flawlessbiological shield without
looking at the study'sscientific red flags.
SPEAKER_01 (12:02):
And the red flags are significant.
They largely stem from thenature of observational cohort
studies.
SPEAKER_00 (12:08):
Which is what just was.
SPEAKER_01 (12:09):
Right.
In a controlled clinical trial,you dictate exactly who gets
what.
But in a cohort study likeSternberg's, you are just
observing people out in the wildover a decade.
SPEAKER_00 (12:18):
You're seeing what happens naturally.
SPEAKER_01 (12:19):
Exactly.
The researchers tried to mimicreal-world conditions by keeping
the inclusion criteria broad.
Basically, it just asks, did youtake a lipid lowering drug or
not?
Okay.
But their exclusion criteriacreated a major blind spot.
They specifically excludedanyone receiving anti-diabetic
or antihypertensive therapies.
SPEAKER_00 (12:37):
Wait, what?
Which knocks out a hugepercentage of the elderly
population.
SPEAKER_01 (12:41):
A massive percentage, yes.
SPEAKER_00 (12:43):
Why would the researchers do that?
Yeah.
Why exclude the exact people whoare most likely to be taking a
heart medication in the firstplace?
SPEAKER_01 (12:49):
Aaron Powell They kind of had to exclude them
because of something calledvascular confounding.
SPEAKER_00 (12:54):
Vascular confounding.
SPEAKER_01 (12:55):
Yeah.
High blood pressure physicallydamages the tiny microvessels in
the brain, and diabetes severelyimpairs how the brain processes
glucose.
Right.
Both of those conditionsindependently accelerate
cognitive decline.
If the researchers had includedpatients on blood pressure and
diabetes medications, theywouldn't really know if the
(13:17):
cognitive scores were changingbecause of the cholesterol drugs
or just because the patient'sblood pressure was finally under
control.
Trevor Burrus, Jr.
SPEAKER_00 (13:24):
Oh, that makes sense.
You wouldn't know which drug wasdoing the heavy lifting.
SPEAKER_01 (13:26):
Aaron Powell Exactly.
But by excluding them, itseverely limits how well these
findings actually apply to thegeneral public, where these
conditions usually, you know,travel together.
SPEAKER_00 (13:36):
Aaron Powell So the data is incredibly clean, but
arguably disconnected from themessy reality of an average
patient's medicine cabinet.
SPEAKER_01 (13:45):
Aaron Powell That's a fair assessment.
SPEAKER_00 (13:46):
Aaron Powell And on top of that, the study lumped
all lipid-lowering regimens intoone big bucket, right?
Like they didn't separate thedifferent classes of drugs.
SPEAKER_01 (13:56):
Aaron Ross Powell That is another major
limitation.
The vast majority of the drugstaken were statins, but not all
statins are identical.
Right.
Some are lipophilic, meaningthey can easily cross the
blood-brain barrier and enterthe brain tissue directly.
While others are hydrophilic,meaning they largely stay in the
bloodstream and act strictly onthe liver.
By pooling them all together,the study obscures which
(14:20):
specific biochemical mechanismis actually providing that 0.17
point benefit.
Trevor Burrus, Jr.
SPEAKER_00 (14:24):
That's frustrating.
SPEAKER_01 (14:25):
Trevor Burrus, Jr.
It is.
But the most glaring biologicalmystery of this entire study,
and honestly, the reasonneurologists remain so cautious
is the complete lack of physicalbiomarker confirmation.
SPEAKER_00 (14:35):
Aaron Powell Right.
Let's dig into that physicalevidence in the brain.
What did the MRI scans and thespinal taps actually show in the
people taking these drugs?
SPEAKER_01 (14:43):
Aaron Powell Well, they showed absolutely no
significant differences.
SPEAKER_00 (14:46):
None at all.
SPEAKER_01 (14:47):
None.
First, the researchers looked atheppocampal atrophy, which is
the physical shrinkage of thebrain's memory center.
The brains of the patients onthe cholesterol drugs were
shrinking at the exact same rateas the patients who weren't.
Wow.
Second, they looked atcerebrospinal fluid tau
concentrations.
SPEAKER_00 (15:04):
Aaron Ross Powell And Tau is essentially the
biological scaffolding of aneuron, right?
SPEAKER_01 (15:08):
Yeah, think of tau like the railroad ties holding
the transport tracks of a braincell together.
SPEAKER_00 (15:14):
Okay, good visual.
SPEAKER_01 (15:15):
In Alzheimer's, those ties disintegrate, the
tracks collapse, and they tangleup.
That structural collapse washappening just as fast in the
statin group.
Jeez.
And finally, there was nodifference in brake staging,
which is the method pathologistsuse to map how far the disease
has physically spread outwardfrom the memory center into the
rest of the cortex.
SPEAKER_00 (15:34):
Okay, this is where my brain starts to break a
little bit.
It is like looking under thehood of a car and seeing that
the engine is rusting, the sparkplugs are dead, and the
transmission is shot at theexact same rate as the car next
to it.
SPEAKER_01 (15:46):
Right.
SPEAKER_00 (15:46):
But somehow your car is driving an extra 10,000 miles
before it breaks down.
SPEAKER_01 (15:50):
That's a great analogy.
SPEAKER_00 (15:52):
If the physical brain shrinkage, the tau
collapse, and the spreadingpathology are all marching along
identically, how on earth is thepatient's actual real-world
memory holding on longer?
SPEAKER_01 (16:03):
That is the central paradox we are currently
grappling with.
The absence of changes in thosephysical biomarkers indicates
that the lipid-lowering drugs donot have a disease-modifying
effect.
SPEAKER_00 (16:14):
Meaning they aren't stopping the root cause.
SPEAKER_01 (16:16):
Exactly.
They aren't stopping the coreAlzheimer's pathology.
What they might be doing,though, is providing a symptom
modifying effect through acompletely parallel pathway.
SPEAKER_00 (16:26):
Like what?
SPEAKER_01 (16:27):
Well, for example, by drastically improving the
health of the endothelial cellslining the brain's blood
vessels, the drugs might bereducing systemic inflammation,
which would allow the brain tofunction better despite the
creeping Alzheimer's pathology.
But we do have to acknowledgethat observational studies are
vulnerable to bias, which cansometimes artificially inflate
(16:47):
how effective a treatment looks.
SPEAKER_00 (16:49):
So, what does this all mean for the listener?
We have a drug class that ischeap, safe, and heavily
prescribed, which might give youa compounding fractional benefit
that buys you precious months ofcognitive function.
Right.
Yet we don't fully understandthe biological mechanism, and
the drugs don't actually stopthe brain from physically
shrinking.
Where does this leave the futureof Alzheimer's treatment?
SPEAKER_01 (17:11):
This raises an important question about our
entire philosophy of treatingage-related cognitive decline.
Because the effects of theselipid-lowering regimens are
modest and don't stop the corepathology, we just cannot look
at them as a standalone magicbullet.
SPEAKER_00 (17:25):
Right.
There is no single pill.
SPEAKER_01 (17:27):
No.
The future is clearlycombinatorial.
Hartman's editorial specificallypoints out that future clinical
trials must evaluate statins incombination with things like the
finger protocol.
SPEAKER_00 (17:37):
I'm so glad you brought up the finger protocol.
That is the finished geriatricintervention study.
Right.
SPEAKER_01 (17:42):
That's the one.
SPEAKER_00 (17:43):
It isn't just about taking a pill, it is a highly
structured, multidomainapproach.
SPEAKER_01 (17:47):
Exactly.
The finger interventionrigorously combines nutritional
guidance, intensive physicalexercise, targeted cognitive
training, and strict monitoringof vascular risk factors all at
once.
SPEAKER_00 (18:00):
It's a whole lifestyle overhaul.
SPEAKER_01 (18:01):
It is.
Hartman suggests that if welayer the modest, compounding
benefit of a targeted lipidlowering drug on top of the
profound lifestyle resiliencebuilt by something like the
finger protocol, we mightfinally outpace the disease.
SPEAKER_00 (18:14):
That makes a lot of sense.
SPEAKER_01 (18:15):
But to do that effectively, we urgently need
rigorous controlled trials tofigure out exactly which
specific cholesterol agentscross the blood-brain barrier
best and how they interact withTau and amyloid in a living
patient.
SPEAKER_00 (18:29):
Yeah, we have to stop looking for a single hero
to save the day and startbuilding a comprehensive
overlapping defense strategy forthe brain.
SPEAKER_01 (18:36):
Absolutely.
SPEAKER_00 (18:37):
So to recap the journey we have been on today,
we started with a smudged cluein a 1907 medical paper where
Allois Alzheimer's first noticedlipid accumulation in brain
cells.
That forgotten detail, combinedwith our modern understanding of
the ApoE4 gene, led us tomassive data sets showing that
common cholesterol drugs canexert a tiny but statistically
(18:58):
real effect on cognitivedecline.
SPEAKER_01 (19:01):
A small effect, but real.
SPEAKER_00 (19:02):
And thanks to the brilliant trajectory math of
time saved, we know thosefractional points can compound
to buy a family real meaningfulmonths together.
SPEAKER_01 (19:12):
Yeah, we are still left staring down a profound
biological mystery as thephysical damage to the brain's
memory center continuescompletely unchecked by these
medications.
SPEAKER_00 (19:22):
And to you listening right now, this is exactly why
diving deep into these primaryscientific sources is so
critical.
It protects you from thewhiplash of internet headlines.
SPEAKER_01 (19:32):
It really does.
SPEAKER_00 (19:32):
You don't have to choose between believing statins
are a miracle cure for dementiaor statins are totally useless.
You get to hold the nuancedtruth.
SPEAKER_01 (19:40):
Ah.
SPEAKER_00 (19:40):
They are a powerful, pragmatic tool with complex
limitations that we are stillfiguring out.
SPEAKER_01 (19:46):
As we wrap up this analysis, I want to leave you
with one final thought toponder.
SPEAKER_00 (19:49):
Please do.
SPEAKER_01 (19:50):
If these common cardiovascular medications can
successfully buy patients monthsof cognitive function, and yet
they do so without altering theclassic physical hallmarks of
Alzheimer's like teltangles andhippocampal shrinkage, could it
be that the progression ofdementia is being driven by
entirely separate whole bodymechanisms?
Wow.
Could the real battleground forour memories not just be inside
(20:13):
the neurons, but in the vastcomplex vascular system that
feeds them, working in ways weare only just beginning to
uncover?
SPEAKER_00 (20:20):
It is a brilliant question to end on.
It makes you wonder if fixingthe body to save the mind isn't
just a metaphor after all, butthe actual biological blueprint
we have been searching for.
It just took us a century tofinally wipe the smudge off the
window and look at the wholepicture.
Imagine looking at uh like a century-old crime
scene photo.
You know, you were staring atthis grainy image trying to
figure out what happened, andyou realize the most important
clue wasn't the smoking gunlying right in the center of the
room.
SPEAKER_01 (00:12):
Aaron Powell Right.
It's usually somethingcompletely unexpected.
SPEAKER_00 (00:16):
Exactly.
It was just the smudge on thewindow that everyone completely
ignored because they were, Imean, they were too distracted
by the obvious evidence.
SPEAKER_01 (00:23):
Aaron Powell Yeah, that happens a lot in science,
actually.
SPEAKER_00 (00:25):
Aaron Powell It really does.
And if you've ever wondered iffixing your whole body could
actually, you know, save yourmind, well, this deep diet is
entirely for you.
Because back in 1907, the doctorwho first discovered Alzheimer's
left us exactly that kind ofoverlooked clue.
SPEAKER_01 (00:43):
Aaron Powell It is just a phenomenal example of how
scientific progress isn't uhit's not always a straight line.
We often have to dig throughthese historical archives to
make sense of the latestclinical data.
Yeah.
Especially when we are dealingwith a disease that has frankly
outsmarted us for this long.
SPEAKER_00 (01:00):
And the source we are analyzing today forces us to
do exactly that.
We are pulling from an editorialpublished in the 2026 Journal of
Prevention of Alzheimer'sDisease.
SPEAKER_01 (01:10):
Written by Tobias Hartman, right?
SPEAKER_00 (01:11):
Yes, Tobias Hartman.
It is titled Lipid LoweringRegimens in Alzheimer's Disease
Dementia, Small Effects withPotential Long-Terfit?
SPEAKER_01 (01:19):
Quite a mouthful.
SPEAKER_00 (01:20):
It is, yeah.
But the mission for this deepdive is to basically synthesize
this dense medical text andanswer a really specific
critical question.
Can common heart medications, uhspecifically drugs that lower
your cholesterol, actually slowdown the cognitive decline of
Alzheimer's?
SPEAKER_01 (01:39):
Which is a huge question.
SPEAKER_00 (01:41):
Huge.
Okay, let's unpack this.
Because to understand why modernneurologists are suddenly so
obsessed with cholesterol drugs,we have to travel back to the
very first time Alzheimer's wasever officially characterized.
SPEAKER_01 (01:51):
Yeah, we have to go all the way back to Alice
Alzheimer's original 1907 paper.
Right.
When he first examined the braintissue of a patient who had died
from this, well, this mysterioussevere dementia, he identified
three distinct molecularhallmarks under his microscope.
SPEAKER_00 (02:05):
Aaron Ross Powell Three of them.
And we usually only hear abouttwo.
SPEAKER_01 (02:08):
Exactly.
The first two hallmarks becamethe cornerstone of a century of
research.
We are talking aboutneurofibrillary tangles and
amyloid plaques.
SPEAKER_00 (02:18):
The famous plaques and tangles.
SPEAKER_01 (02:20):
Right.
Those two structural anomalieshave just dominated billions of
dollars in funding.
But Alzheimer's actuallydocumented a third hallmark in
that very same paper.
He called them uh glial adiposesacches.
SPEAKER_00 (02:34):
Okay, I have read a lot about plaques and tangles
over the years, but glialadipose sacules is definitely a
new one for me.
SPEAKER_01 (02:41):
It sounds very archaic.
SPEAKER_00 (02:42):
It really does.
Break down thatturn-of-the-century terminology
for it.
SPEAKER_01 (02:45):
Sure.
So in modern biological terms,he was describing intracellular
lipid accumulation.
SPEAKER_00 (02:50):
Aaron Ross Powell Meaning fat inside the cells.
SPEAKER_01 (02:52):
Basically, yeah.
He saw these little droplets offat building up inside the
brain's support cells, which arethe glia.
Wow.
But for the better part of acentury, that observation was
totally sidelined.
I mean, the scientific communitylooked at those fat droplets and
assumed they were just abyproduct of dying brain tissue.
Trevor Burrus, Jr.
SPEAKER_00 (03:08):
Like just trash left over from the damage.
SPEAKER_01 (03:10):
Aaron Ross Powell Exactly.
Kind of like debris left overafter a building collapses, you
know.
The tangles and the plaques wereviewed as the main event.
SPEAKER_00 (03:18):
Okay.
SPEAKER_01 (03:19):
And it wasn't until about 30 years ago that the
journal Science published thisreally provocative article
titled Bad for the Heart, Badfor the Mind, which finally
challenged that wholeassumption.
SPEAKER_00 (03:29):
Aaron Powell And that article started connecting
the dots between cardiovascularhealth and brain health, right?
Trevor Burrus, Jr.
SPEAKER_01 (03:35):
It did.
SPEAKER_00 (03:35):
Because they noticed that statins were doing
something unexpected.
SPEAKER_01 (03:38):
Aaron Powell Yeah.
That science article highlightedsome early epidemiological data
suggesting that statins, whichare, you know,
cholesterol-lowering drugs,might actually lower amyloid
beta in the brain.
But more importantly, itcoincided with a growing
understanding of the genetics ofAlzheimer's.
We realized around then that thestrongest genetic risk factor
(04:01):
for late-onset Alzheimer's is agene variant called ApoE4.
SPEAKER_00 (04:05):
Aaron Ross Powell, which is something anyone who
has taken a commercial DNA testfor health risks has probably
heard of.
Like it pops up all the time.
SPEAKER_01 (04:11):
Oh, absolutely.
It's very well known now.
SPEAKER_00 (04:13):
Aaron Ross Powell But how does ApoE4 actually
connect to those little fatdroplets Alzheimer's song?
SPEAKER_01 (04:18):
Aaron Ross Powell Well, what is remarkable is that
ApoE's literal day job in thehuman body is lipid transport.
It is an apolipoprotein.
Okay.
So its primary function is tophysically carry cholesterol and
other fats through thebloodstream and the brain.
SPEAKER_00 (04:33):
Wow.
So if the biggest genetic riskfactor for the disease is
basically a broken cholesteroldelivery truck.
SPEAKER_01 (04:39):
Exactly.
SPEAKER_00 (04:40):
And Alice Alzheimer saw fat accumulating in the
brain cells all the way back in1907, the connection becomes
kind of undeniable.
SPEAKER_01 (04:49):
It does.
It shows the lipid system isfundamentally involved in the
pathology.
SPEAKER_00 (04:53):
So the historical blind spot wasn't just like a
miss detail.
It was a fundamentalmisunderstanding of the brain's
metabolism.
Right.
Spent decades staring at theplaques, completely ignoring the
fact that the brain's fattransport system was breaking
down right in front of us.
SPEAKER_01 (05:06):
What's fascinating here is how this realization
completely shifted the paradigmof modern prevention strategies.
Also.
Well, we finally recognized thatsystemic factors like elevated
midlife cholesterol are majormodifiable risk factors for the
disease.
SPEAKER_00 (05:22):
Aaron Powell Modifiable meaning we can
actually do something aboutthem.
SPEAKER_01 (05:25):
Exactly.
We stopped looking at the brainas this isolated fortress that
just operates independently ofthe rest of the body.
And that brings us to thepresent day, where researchers
are trying to see if we canmanipulate that cholesterol
system to actually change thecourse of the dementia.
SPEAKER_00 (05:40):
Which brings us to the clinical data at the center
of the Hartman editorial.
Because this isn't justtheoretical biology anymore.
SPEAKER_01 (05:46):
No, not at all.
SPEAKER_00 (05:47):
Hartman focuses on a massive perspective study by
Sternberg and colleagues.
And when I say massive, I meanthey followed nearly 50,000
participants for 10 years.
SPEAKER_01 (05:57):
Aaron Powell It is an incredibly robust data set.
Sternberg's team wanted tomeasure the actual impact of
lipid lowering regimens oncognitive decline over time.
So they tracked participantsmoving from normal cognition
into mild cognitive impairmentor MCI, and then subsequently
into full dementia.
SPEAKER_00 (06:15):
Aaron Powell And how do they measure that?
Like what's the ruler they use?
SPEAKER_01 (06:17):
Aaron Powell To quantify that decline, they use
something called the CDRSB,which stands for Clinical
Dementia Rating Sum of Boxes.
SPEAKER_00 (06:25):
Sum of boxes.
SPEAKER_01 (06:26):
Yeah.
It is a standard scaleneurologist use to score a
patient's memory, orientation,judgment, and personal care.
The higher the score, the worsethe impairment.
SPEAKER_00 (06:36):
Aaron Powell Okay, and with 50,000 people over a
full decade, you get the kind ofstatistical power that can
detect even the tiniestfluctuations in human cognition.
SPEAKER_01 (06:46):
Exactly.
You can see the smallestsignals.
SPEAKER_00 (06:48):
Aaron Powell But I have to bring up the actual
numbers they found.
Because I read this, and for thegroup converting from normal
cognition to mild cognitiveimpairment, the researchers
found a difference of elevenhundredth of a CDRSB point per
year compared to non-users.
SPEAKER_01 (07:02):
That is the reported figure, yes.
An annual difference of.01points.
SPEAKER_00 (07:06):
Wait, eleven hundredth of a point?
SPEAKER_01 (07:08):
Yeah.
SPEAKER_00 (07:08):
Is that even worth putting in a medical journal,
let alone discussing here?
I mean, a human being's mood ona random Tuesday could probably
fluctuate their memory test bymore than eleven hundredth of a
point.
That sounds like a statisticalrounding error, not a medical
breakthrough.
SPEAKER_01 (07:23):
Your skepticism is entirely justified, and you
know, the editorial actuallyvalidates that exact pushback.
In a standard clinical setting,eleven hundredth of a point is
entirely negligible.
Right.
A patient and their family wouldabsolutely never notice that
kind of difference day to day.
But the researchers didn't juststop there.
Okay.
When they stratified the dataand looked at a different subset
(07:44):
of patients, the narrativechanged pretty significantly.
They looked at individuals olderthan 50 who already had a higher
degree of baseline cognitiveimpairment.
SPEAKER_00 (07:52):
So people who are already showing real symptoms.
SPEAKER_01 (07:55):
Yeah, specifically people with a CDRSB score
greater than three.
For that group, the benefit ofthe lipid lowering drugs
increased to a reduction of 0.17points annually.
SPEAKER_00 (08:05):
Okay, well, 0.17 is undeniably larger than 0.01.
SPEAKER_01 (08:08):
Definitely.
SPEAKER_00 (08:09):
But let's be honest, to the average listener trying
to figure out how to help, say,a parent with dementia, 0.17
still sounds pretty microscopic.
SPEAKER_01 (08:17):
It does sound small.
SPEAKER_00 (08:18):
We need to bridge the gap between abstract
clinical statistics and humanreality here.
SPEAKER_01 (08:23):
Uh-huh.
SPEAKER_00 (08:24):
Why does the scientific community care so
much about a 0.17 annualreduction?
SPEAKER_01 (08:29):
Because in neurodegenerative diseases, we
have to translate these abstractpoint scores into the one metric
that actually matters topatients, which is time.
SPEAKER_00 (08:39):
Time.
SPEAKER_01 (08:40):
Yes.
The editorial introduces thisreally brilliant analytical
concept called time saved.
It references the recentmethodological work by
researchers Dixon and Hendricks.
SPEAKER_00 (08:50):
Okay, and what did they do?
SPEAKER_01 (08:52):
They developed a mathematical model to convert
these tiny fractionaldifferences on the CDRSB scale
into actual months of lifegained.
SPEAKER_00 (09:00):
How do they actually calculate that though?
Yeah.
Because time saved sounds greatin a brochure, but how does the
math actually work in a clinicaltrial?
SPEAKER_01 (09:08):
It is based on mapping the trajectory of
decline.
SPEAKER_00 (09:11):
Okay.
SPEAKER_01 (09:11):
Imagine drawing a downward sloping line that
represents how fast the placebogroup is losing their cognitive
function over a year.
SPEAKER_00 (09:17):
Aaron Powell Right.
So a steady slope downwards.
SPEAKER_01 (09:19):
Then you plot the treatment group's decline on the
exact same graph.
Because the treatment group isdeclining slightly slower, say
0.17 points slower, their lineis a bit flatter.
SPEAKER_00 (09:29):
Uh-huh.
SPEAKER_01 (09:30):
The time saved is calculated by looking at where
the treatment group ended up atthe end of the trial, and then
tracing horizontally to see howmany months earlier the placebo
group hit that exact same levelof impairment.
SPEAKER_00 (09:41):
Oh wow.
So it is literally measuring thegap in time between when the two
groups crossed the exact samethreshold of memory loss.
SPEAKER_01 (09:48):
Precisely.
To give you some context for howthis looks in practice, Hendrix
evaluated the high-profileAlzheimer's drug Donamab.
SPEAKER_00 (09:55):
Right.
That's been in the news a lot.
SPEAKER_01 (09:57):
It has.
In its clinical trials, Donomabshowed a CDR SB difference of
0.36 points over 76 weeks.
Okay.
When they ran that trajectorymath, that fractional point
difference translated todelaying the disease progression
by about 5.2 months.
SPEAKER_00 (10:14):
That's almost half a year.
SPEAKER_01 (10:15):
Exactly.
Another intervention they lookedat, Fortis and Connect, showed a
0.6 point difference over 24months, which translated to a
delay of 10.5 months.
SPEAKER_00 (10:25):
Here's where it gets really interesting.
If we apply that trajectory mathto these standard cholesterol
drugs, the whole perspectiveshifts, right?
SPEAKER_01 (10:32):
It really does.
If an older patient with mildimpairment is seeing a 0.17
point reduction annually fromtheir lipid lowering regimen,
you are looking at a compoundingeffect over time.
SPEAKER_00 (10:43):
Aaron Powell I like to think of it like putting
loose change in a jar ratherthan trying to, you know, win
the lottery.
SPEAKER_01 (10:49):
That's a great way to look at it.
SPEAKER_00 (10:50):
Taking a statin isn't going to cure the disease
overnight.
But if you are saving a fractionof a point this year and another
fraction next year and the yearafter that, I mean, over a five
or ten year period, thatcompounding interest suddenly
buys you real meaningful time.
SPEAKER_01 (11:06):
Absolutely.
SPEAKER_00 (11:07):
You are talking about potentially extending a
person's ability to recognizetheir grandchildren or manage
their own household by severalmonths.
SPEAKER_01 (11:16):
If we connect this to the bigger picture, this is
exactly why the scientificcommunity is paying so much
attention.
Yeah.
A sustained compoundingreduction of 0.17 points
annually transforms what lookslike a modest statistical blip
into a profoundly meaningfulclinical outcome.
Buying six months of cognitiveindependence is a triumph in
Alzheimer's care.
SPEAKER_00 (11:37):
It is a massive triumph.
But wait, if this compoundingmath is so incredibly promising,
why isn't every neurologist onthe planet just aggressively
prescribing cholesterolmedications specifically for
dementia right now?
SPEAKER_01 (11:50):
Well, that's the catch.
SPEAKER_00 (11:51):
Right.
What is the catch in the data?
Because we cannot give you, thelistener, the impression that
statins are this flawlessbiological shield without
looking at the study'sscientific red flags.
SPEAKER_01 (12:02):
And the red flags are significant.
They largely stem from thenature of observational cohort
studies.
SPEAKER_00 (12:08):
Which is what just was.
SPEAKER_01 (12:09):
Right.
In a controlled clinical trial,you dictate exactly who gets
what.
But in a cohort study likeSternberg's, you are just
observing people out in the wildover a decade.
SPEAKER_00 (12:18):
You're seeing what happens naturally.
SPEAKER_01 (12:19):
Exactly.
The researchers tried to mimicreal-world conditions by keeping
the inclusion criteria broad.
Basically, it just asks, did youtake a lipid lowering drug or
not?
Okay.
But their exclusion criteriacreated a major blind spot.
They specifically excludedanyone receiving anti-diabetic
or antihypertensive therapies.
SPEAKER_00 (12:37):
Wait, what?
Which knocks out a hugepercentage of the elderly
population.
SPEAKER_01 (12:41):
A massive percentage, yes.
SPEAKER_00 (12:43):
Why would the researchers do that?
Yeah.
Why exclude the exact people whoare most likely to be taking a
heart medication in the firstplace?
SPEAKER_01 (12:49):
Aaron Powell They kind of had to exclude them
because of something calledvascular confounding.
SPEAKER_00 (12:54):
Vascular confounding.
SPEAKER_01 (12:55):
Yeah.
High blood pressure physicallydamages the tiny microvessels in
the brain, and diabetes severelyimpairs how the brain processes
glucose.
Right.
Both of those conditionsindependently accelerate
cognitive decline.
If the researchers had includedpatients on blood pressure and
diabetes medications, theywouldn't really know if the
(13:17):
cognitive scores were changingbecause of the cholesterol drugs
or just because the patient'sblood pressure was finally under
control.
Trevor Burrus, Jr.
SPEAKER_00 (13:24):
Oh, that makes sense.
You wouldn't know which drug wasdoing the heavy lifting.
SPEAKER_01 (13:26):
Aaron Powell Exactly.
But by excluding them, itseverely limits how well these
findings actually apply to thegeneral public, where these
conditions usually, you know,travel together.
SPEAKER_00 (13:36):
Aaron Powell So the data is incredibly clean, but
arguably disconnected from themessy reality of an average
patient's medicine cabinet.
SPEAKER_01 (13:45):
Aaron Powell That's a fair assessment.
SPEAKER_00 (13:46):
Aaron Powell And on top of that, the study lumped
all lipid-lowering regimens intoone big bucket, right?
Like they didn't separate thedifferent classes of drugs.
SPEAKER_01 (13:56):
Aaron Ross Powell That is another major
limitation.
The vast majority of the drugstaken were statins, but not all
statins are identical.
Right.
Some are lipophilic, meaningthey can easily cross the
blood-brain barrier and enterthe brain tissue directly.
While others are hydrophilic,meaning they largely stay in the
bloodstream and act strictly onthe liver.
By pooling them all together,the study obscures which
(14:20):
specific biochemical mechanismis actually providing that 0.17
point benefit.
Trevor Burrus, Jr.
SPEAKER_00 (14:24):
That's frustrating.
SPEAKER_01 (14:25):
Trevor Burrus, Jr.
It is.
But the most glaring biologicalmystery of this entire study,
and honestly, the reasonneurologists remain so cautious
is the complete lack of physicalbiomarker confirmation.
SPEAKER_00 (14:35):
Aaron Powell Right.
Let's dig into that physicalevidence in the brain.
What did the MRI scans and thespinal taps actually show in the
people taking these drugs?
SPEAKER_01 (14:43):
Aaron Powell Well, they showed absolutely no
significant differences.
SPEAKER_00 (14:46):
None at all.
SPEAKER_01 (14:47):
None.
First, the researchers looked atheppocampal atrophy, which is
the physical shrinkage of thebrain's memory center.
The brains of the patients onthe cholesterol drugs were
shrinking at the exact same rateas the patients who weren't.
Wow.
Second, they looked atcerebrospinal fluid tau
concentrations.
SPEAKER_00 (15:04):
Aaron Ross Powell And Tau is essentially the
biological scaffolding of aneuron, right?
SPEAKER_01 (15:08):
Yeah, think of tau like the railroad ties holding
the transport tracks of a braincell together.
SPEAKER_00 (15:14):
Okay, good visual.
SPEAKER_01 (15:15):
In Alzheimer's, those ties disintegrate, the
tracks collapse, and they tangleup.
That structural collapse washappening just as fast in the
statin group.
Jeez.
And finally, there was nodifference in brake staging,
which is the method pathologistsuse to map how far the disease
has physically spread outwardfrom the memory center into the
rest of the cortex.
SPEAKER_00 (15:34):
Okay, this is where my brain starts to break a
little bit.
It is like looking under thehood of a car and seeing that
the engine is rusting, the sparkplugs are dead, and the
transmission is shot at theexact same rate as the car next
to it.
SPEAKER_01 (15:46):
Right.
SPEAKER_00 (15:46):
But somehow your car is driving an extra 10,000 miles
before it breaks down.
SPEAKER_01 (15:50):
That's a great analogy.
SPEAKER_00 (15:52):
If the physical brain shrinkage, the tau
collapse, and the spreadingpathology are all marching along
identically, how on earth is thepatient's actual real-world
memory holding on longer?
SPEAKER_01 (16:03):
That is the central paradox we are currently
grappling with.
The absence of changes in thosephysical biomarkers indicates
that the lipid-lowering drugs donot have a disease-modifying
effect.
SPEAKER_00 (16:14):
Meaning they aren't stopping the root cause.
SPEAKER_01 (16:16):
Exactly.
They aren't stopping the coreAlzheimer's pathology.
What they might be doing,though, is providing a symptom
modifying effect through acompletely parallel pathway.
SPEAKER_00 (16:26):
Like what?
SPEAKER_01 (16:27):
Well, for example, by drastically improving the
health of the endothelial cellslining the brain's blood
vessels, the drugs might bereducing systemic inflammation,
which would allow the brain tofunction better despite the
creeping Alzheimer's pathology.
But we do have to acknowledgethat observational studies are
vulnerable to bias, which cansometimes artificially inflate
(16:47):
how effective a treatment looks.
SPEAKER_00 (16:49):
So, what does this all mean for the listener?
We have a drug class that ischeap, safe, and heavily
prescribed, which might give youa compounding fractional benefit
that buys you precious months ofcognitive function.
Right.
Yet we don't fully understandthe biological mechanism, and
the drugs don't actually stopthe brain from physically
shrinking.
Where does this leave the futureof Alzheimer's treatment?
SPEAKER_01 (17:11):
This raises an important question about our
entire philosophy of treatingage-related cognitive decline.
Because the effects of theselipid-lowering regimens are
modest and don't stop the corepathology, we just cannot look
at them as a standalone magicbullet.
SPEAKER_00 (17:25):
Right.
There is no single pill.
SPEAKER_01 (17:27):
No.
The future is clearlycombinatorial.
Hartman's editorial specificallypoints out that future clinical
trials must evaluate statins incombination with things like the
finger protocol.
SPEAKER_00 (17:37):
I'm so glad you brought up the finger protocol.
That is the finished geriatricintervention study.
Right.
SPEAKER_01 (17:42):
That's the one.
SPEAKER_00 (17:43):
It isn't just about taking a pill, it is a highly
structured, multidomainapproach.
SPEAKER_01 (17:47):
Exactly.
The finger interventionrigorously combines nutritional
guidance, intensive physicalexercise, targeted cognitive
training, and strict monitoringof vascular risk factors all at
once.
SPEAKER_00 (18:00):
It's a whole lifestyle overhaul.
SPEAKER_01 (18:01):
It is.
Hartman suggests that if welayer the modest, compounding
benefit of a targeted lipidlowering drug on top of the
profound lifestyle resiliencebuilt by something like the
finger protocol, we mightfinally outpace the disease.
SPEAKER_00 (18:14):
That makes a lot of sense.
SPEAKER_01 (18:15):
But to do that effectively, we urgently need
rigorous controlled trials tofigure out exactly which
specific cholesterol agentscross the blood-brain barrier
best and how they interact withTau and amyloid in a living
patient.
SPEAKER_00 (18:29):
Yeah, we have to stop looking for a single hero
to save the day and startbuilding a comprehensive
overlapping defense strategy forthe brain.
SPEAKER_01 (18:36):
Absolutely.
SPEAKER_00 (18:37):
So to recap the journey we have been on today,
we started with a smudged cluein a 1907 medical paper where
Allois Alzheimer's first noticedlipid accumulation in brain
cells.
That forgotten detail, combinedwith our modern understanding of
the ApoE4 gene, led us tomassive data sets showing that
common cholesterol drugs canexert a tiny but statistically
(18:58):
real effect on cognitivedecline.
SPEAKER_01 (19:01):
A small effect, but real.
SPEAKER_00 (19:02):
And thanks to the brilliant trajectory math of
time saved, we know thosefractional points can compound
to buy a family real meaningfulmonths together.
SPEAKER_01 (19:12):
Yeah, we are still left staring down a profound
biological mystery as thephysical damage to the brain's
memory center continuescompletely unchecked by these
medications.
SPEAKER_00 (19:22):
And to you listening right now, this is exactly why
diving deep into these primaryscientific sources is so
critical.
It protects you from thewhiplash of internet headlines.
SPEAKER_01 (19:32):
It really does.
SPEAKER_00 (19:32):
You don't have to choose between believing statins
are a miracle cure for dementiaor statins are totally useless.
You get to hold the nuancedtruth.
SPEAKER_01 (19:40):
Ah.
SPEAKER_00 (19:40):
They are a powerful, pragmatic tool with complex
limitations that we are stillfiguring out.
SPEAKER_01 (19:46):
As we wrap up this analysis, I want to leave you
with one final thought toponder.
SPEAKER_00 (19:49):
Please do.
SPEAKER_01 (19:50):
If these common cardiovascular medications can
successfully buy patients monthsof cognitive function, and yet
they do so without altering theclassic physical hallmarks of
Alzheimer's like teltangles andhippocampal shrinkage, could it
be that the progression ofdementia is being driven by
entirely separate whole bodymechanisms?
Wow.
Could the real battleground forour memories not just be inside
(20:13):
the neurons, but in the vastcomplex vascular system that
feeds them, working in ways weare only just beginning to
uncover?
SPEAKER_00 (20:20):
It is a brilliant question to end on.
It makes you wonder if fixingthe body to save the mind isn't
just a metaphor after all, butthe actual biological blueprint
we have been searching for.
It just took us a century tofinally wipe the smudge off the
window and look at the wholepicture.
Popular Podcasts
Dateline NBC
Current and classic episodes, featuring compelling true-crime mysteries, powerful documentaries and in-depth investigations. Follow now to get the latest episodes of Dateline NBC completely free, or subscribe to Dateline Premium for ad-free listening and exclusive bonus content: DatelinePremium.com
Hey Jonas!
Hey Jonas! The official Jonas Brothers podcast. Hosted by Kevin, Joe, and Nick Jonas. It’s the Jonas Brothers you know... musicians, actors, and well, yes, brothers. Now, they’re sharing another side of themselves in the playful, intimate, and irreverent way only they can. Spend time with the Jonas Brothers here and stay a little bit longer for deep conversations like never before.
Betrayal Weekly
Betrayal Weekly is back for a new season. Every Thursday, Betrayal Weekly shares first-hand accounts of broken trust, shocking deceptions, and the trail of destruction they leave behind. Hosted by Andrea Gunning, this weekly ongoing series digs into real-life stories of betrayal and the aftermath. From stories of double lives to dark discoveries, these are cautionary tales and accounts of resilience against all odds. From the producers of the critically acclaimed Betrayal series, Betrayal Weekly drops new episodes every Thursday. If you would like to share your story, you can reach out to the Betrayal Team by emailing them at betrayalpod@gmail.com and follow us on Instagram at @betrayalpod and @glasspodcasts. Please join our Substack for additional exclusive content, curated book recommendations, and community discussions. Sign up FREE by clicking this link Beyond Betrayal Substack. Join our community dedicated to truth, resilience, and healing. Your voice matters! Be a part of our Betrayal journey on Substack.